Roth Capital Reiterates Buy Rating for Aptose Biosciences Inc (APS)
Separately, HC Wainwright restated a “buy” rating on shares of Aptose Biosciences in a research note on Thursday, September 7th.
Aptose Biosciences (TSE APS) opened at 1.85 on Monday. The stock’s 50 day moving average price is $1.84 and its 200-day moving average price is $1.67. Aptose Biosciences has a 12 month low of $1.05 and a 12 month high of $2.38. The firm’s market capitalization is $44.45 million.
WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/25/roth-capital-reiterates-buy-rating-for-aptose-biosciences-inc-aps.html.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Receive News & Ratings for Aptose Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.